Search

Displaying results 9781 - 9790 of 10000 in total
  1. Drug

    ARQ 171

    go.drugbank.com/drugs/DB06034
    Investigational

  2. Drug

    Tezacitabine

    go.drugbank.com/drugs/DB06433
    Investigational

    A synthetic purine nucleoside analogue with potential antineoplastic activity.

    Synonyms: 2'-Deoxy-2'-(fluoromethylene)cytidineCategories: Heterocyclic Compounds, 1-Ring
  3. Drug

    Azvudine

    go.drugbank.com/drugs/DB16407
    Investigational

    Azvudine is under investigation in clinical trial NCT04668235 (Study on Safety and Clinical Efficacy of AZVUDINE in COVID-19 Patients (Sars-cov-2 Infected)).

    Categories: Heterocyclic Compounds, 1-Ring
  4. Drug

    Adomiparin

    go.drugbank.com/drugs/DB06005
    Investigational

  5. Drug

    Exisulind

    go.drugbank.com/drugs/DB06246
    Investigational

    Synonyms: 5-Fluoro-2-methyl-1-((Z)-p-(methylsulfonyl)benzylidene)indene-3-acetic acid, cis-5-Fluoro-2-methyl-1-(p-methylsulfonylbenzylidenyl)indene-3-acetic acidCategories: Compounds used in a research, industrial, or household setting
  6. Drug

    Ocaperidone

    go.drugbank.com/drugs/DB06229
    Experimental

    Categories: Heterocyclic Compounds, 1-Ring
  7. Drug

    Afizagabar

    go.drugbank.com/drugs/DB21439
    Investigational

    Afizagabar is a small molecule drug. Afizagabar is under investigation in clinical trial NCT02877615 (Efficacy and Safety Trial With S 44819 After Recent Ischemic Cerebral Event). … Afizagabar has a monoisotopic molecular weight of 365.06 Da.

    Categories: GABA-A Receptor Antagonists, Heterocyclic Compounds, 1-Ring
  8. Drug

    E-2012

    go.drugbank.com/drugs/DB05171
    Experimental

    E-2012 is a gamma secretase modulator that is being evaluated as a potential new treatment for Alzheimer's disease.

    Categories: Heterocyclic Compounds, 1-Ring
  9. Drug

    DP-VPA

    go.drugbank.com/drugs/DB05821
    Investigational

    DP-VPA is D-Pharm's proprietary lipid modified version of valproic acid (VPA) that demonstrate that DP-VPA is well-tolerated in patients with resistant epilepsy and has a marked effect on reducing seizure

  10. Drug

    Pazopanib

    go.drugbank.com/drugs/DB06589
    ApprovedInvestigational

    Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.

    Categories: Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index, P-glycoprotein substrates with a Narrow Therapeutic IndexProducts: VOTRIENT® 200 MG, VOTRIENT® 400 MG